ATE273305T1 - Thrombin-inhibitoren - Google Patents

Thrombin-inhibitoren

Info

Publication number
ATE273305T1
ATE273305T1 AT99962534T AT99962534T ATE273305T1 AT E273305 T1 ATE273305 T1 AT E273305T1 AT 99962534 T AT99962534 T AT 99962534T AT 99962534 T AT99962534 T AT 99962534T AT E273305 T1 ATE273305 T1 AT E273305T1
Authority
AT
Austria
Prior art keywords
thrombin inhibitors
formula
anticoagulants
class
compounds
Prior art date
Application number
AT99962534T
Other languages
English (en)
Inventor
Koo Lee
Won Hyuk Jung
Cheol Won Park
Sang Koo Lee
Sun Hwa Lee
Hee Dong Park
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Application granted granted Critical
Publication of ATE273305T1 publication Critical patent/ATE273305T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
AT99962534T 1998-12-29 1999-12-29 Thrombin-inhibitoren ATE273305T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19980060266 1998-12-29
KR1019990033490A KR20000047461A (ko) 1998-12-29 1999-08-14 트롬빈 억제제
PCT/KR1999/000830 WO2000039124A1 (en) 1998-12-29 1999-12-29 Thrombin inhibitors

Publications (1)

Publication Number Publication Date
ATE273305T1 true ATE273305T1 (de) 2004-08-15

Family

ID=26634497

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99962534T ATE273305T1 (de) 1998-12-29 1999-12-29 Thrombin-inhibitoren

Country Status (22)

Country Link
US (2) US6492402B1 (de)
EP (1) EP1140918B1 (de)
JP (1) JP3847092B2 (de)
KR (2) KR20000047461A (de)
CN (1) CN1149210C (de)
AT (1) ATE273305T1 (de)
AU (1) AU765417B2 (de)
BR (1) BR9916678A (de)
CA (1) CA2355281A1 (de)
CZ (1) CZ20012429A3 (de)
DE (1) DE69919397T2 (de)
DK (1) DK1140918T3 (de)
ES (1) ES2226482T3 (de)
HK (1) HK1044936A1 (de)
HU (1) HUP0104500A3 (de)
IL (1) IL143545A (de)
NO (1) NO321739B1 (de)
NZ (1) NZ513174A (de)
RU (1) RU2221808C2 (de)
TR (1) TR200101899T2 (de)
WO (1) WO2000039124A1 (de)
ZA (1) ZA200104780B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL352824A1 (en) * 1999-04-09 2003-09-08 Abbott Gmbh & Co.Kg Prodrugs of thrombin inhibitors
DE19933861A1 (de) * 1999-07-23 2001-01-25 Basf Ag Verfahren zur Herstellung von 2-Aminomethyl-4-cyano-thiazol
DE19934066A1 (de) * 1999-07-23 2001-01-25 Basf Ag Verfahren zur Herstellung von 4-Cyano-2-aminomethylthiazol
DE10049937A1 (de) * 2000-10-06 2002-04-11 Knoll Ag Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten
KR100447421B1 (ko) * 2001-04-04 2004-09-07 주식회사 엘지생명과학 5-(아미노메틸)-2-티오펜카보니트릴 염산염의 연속반응에의한 새로운 제조방법
JP2005526800A (ja) * 2002-03-22 2005-09-08 エルジー・ライフ・サイエンシーズ・リミテッド (2S)−N−5−[アミノ(イミノ)メチル]−2−チエニルメチル−1−(2R)−2−[(カルボキシルメチル)アミノ]−3,3−ジフェニルプロパノイル−2−ピロリジンカルボキサミド・nH2Oの新しい結晶形
CN1642946A (zh) * 2002-03-22 2005-07-20 株式会社Lg生命科学 (2s)-n-{5-[氨基(亚氨基)甲基]-2-噻吩基}甲基-1-{(2r)-2-[(羧甲基)氨基]3,-二苯基丙酰}-2-吡咯烷甲酰胺的马来酸盐及其制备方法
WO2004002985A1 (en) * 2002-06-27 2004-01-08 Lg Life Sciences Ltd. Peptidic thrombin inhibitor compound
US7097967B2 (en) 2002-10-24 2006-08-29 Lg Life Sciences Ltd. Method of predicting drug-food interaction
US7399870B2 (en) * 2004-03-30 2008-07-15 Wyeth Synthesis of pyrrole-2-carbonitriles
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US7678917B2 (en) * 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
CA2651762A1 (en) 2006-05-23 2007-11-29 Irm Llc Compounds and compositions as channel activating protease inhibitors
JP2008115178A (ja) 2006-11-03 2008-05-22 Ajinomoto Co Inc ジフェニルアラニン−Ni(II)錯体の製造方法
AU2008214217B2 (en) 2007-02-09 2011-10-13 Irm Llc Compounds and compositions as channel activating protease inhibitors
WO2008135525A2 (en) * 2007-05-02 2008-11-13 Boehringer Ingelheim International Gmbh Substituted azetidines, manufacturing and use thereof as medicaments
CN102918034B (zh) 2010-03-30 2015-06-03 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
WO2012058645A1 (en) * 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
LT2968297T (lt) 2013-03-15 2019-01-10 Verseon Corporation Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai
ES2791749T3 (es) 2013-03-15 2020-11-05 Verseon Corp Halogenopirazoles como inhibidores de la trombina
CN106687445A (zh) 2014-09-17 2017-05-17 维颂公司 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物
RU2017131562A (ru) 2015-02-27 2019-03-27 Версеон Корпорейшн Замещенные пиразольные соединения как ингибиторы сериновых протеаз
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
IL311042B1 (en) 2018-05-29 2026-04-01 Omeros Corp MASP-2 inhibitors and methods of use
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
KR20210093855A (ko) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 보체 인자 d 억제제의 형태체 형태
WO2020131974A1 (en) 2018-12-17 2020-06-25 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
BR112021018456A2 (pt) * 2019-03-22 2021-11-23 Achillion Pharmaceuticals Inc Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
EP4069676A1 (de) 2019-12-04 2022-10-12 Omeros Corporation Masp-2-hemmer und verfahren zur verwendung
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
IL293588B1 (en) 2019-12-04 2026-04-01 Omeros Corp 3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof
JP7764808B2 (ja) * 2021-08-11 2025-11-06 Jsr株式会社 液晶配向剤、液晶配向膜及びその製造方法、液晶素子並びに重合体
WO2023183405A2 (en) * 2022-03-22 2023-09-28 Alexion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
IL112795A (en) * 1994-03-04 2001-01-28 Astrazeneca Ab Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
FI973282L (fi) 1995-02-10 1997-08-08 Basf Ag Trombiinin inhibiittoreita
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5914319A (en) 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
JP2002501081A (ja) * 1998-01-26 2002-01-15 ビーエーエスエフ アクチェンゲゼルシャフト トロンビンインヒビター
EP1049673A1 (de) * 1998-01-26 2000-11-08 Basf Aktiengesellschaft Heterocyclische amidine als kallikrein protease inhibitoren

Also Published As

Publication number Publication date
KR20010086468A (ko) 2001-09-12
AU1895100A (en) 2000-07-31
CZ20012429A3 (cs) 2001-10-17
EP1140918A1 (de) 2001-10-10
AU765417B2 (en) 2003-09-18
HK1044936A1 (zh) 2002-11-08
JP2002533460A (ja) 2002-10-08
CN1149210C (zh) 2004-05-12
US6864249B2 (en) 2005-03-08
JP3847092B2 (ja) 2006-11-15
ZA200104780B (en) 2003-06-12
WO2000039124A1 (en) 2000-07-06
DE69919397D1 (de) 2004-09-16
US6492402B1 (en) 2002-12-10
DK1140918T3 (da) 2004-12-20
NO20013220L (no) 2001-08-27
NO321739B1 (no) 2006-06-26
RU2221808C2 (ru) 2004-01-20
DE69919397T2 (de) 2005-07-28
NO20013220D0 (no) 2001-06-27
US20030134801A1 (en) 2003-07-17
EP1140918B1 (de) 2004-08-11
HUP0104500A2 (hu) 2002-04-29
KR100462974B1 (ko) 2004-12-23
CN1332737A (zh) 2002-01-23
ES2226482T3 (es) 2005-03-16
BR9916678A (pt) 2001-10-16
IL143545A (en) 2005-08-31
IL143545A0 (en) 2002-04-21
CA2355281A1 (en) 2000-07-06
TR200101899T2 (tr) 2001-12-21
HUP0104500A3 (en) 2002-06-28
NZ513174A (en) 2003-10-31
KR20000047461A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
DE69919397D1 (de) Thrombin-inhibitoren
ATE297203T1 (de) Antithrombotische mitteln
CY1107634T1 (el) Φαρμακευτικη συνθεση
ATE306261T1 (de) Antithrombosemittel
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
ATE272633T1 (de) Aromatische amiden
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
SE9203825D0 (sv) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
EE200200045A (et) Asendatud oksoasaheterotsüklüülühendid, farmatseutiline kompositsioon ja vaheühendid
NO20003018L (no) Triazinangiogenese-inhibitorer
NO991494D0 (no) <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
DE69931393D1 (de) Antithrombotische amide
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
DK0715623T3 (da) Blodpladeaggregationsinhibitorer
UY26780A1 (es) Cicloalquil avb3 antagonistas
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
ATE308540T1 (de) Antithrombosemittel
DK0804418T3 (da) Platelataggregationshæmmere
ATE253359T1 (de) Antithrombotische mittel
NO20022977D0 (no) Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter
DE602004011064D1 (en) Antitrombotische aether

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140918

Country of ref document: EP

REN Ceased due to non-payment of the annual fee